XAIR vs. DRIO, PAVM, ARAY, TELA, QIPT, KRMD, SRTS, BLUA, BWAY, and ALUR
Should you be buying Beyond Air stock or one of its competitors? The main competitors of Beyond Air include DarioHealth (DRIO), PAVmed (PAVM), Accuray (ARAY), TELA Bio (TELA), Quipt Home Medical (QIPT), KORU Medical Systems (KRMD), Sensus Healthcare (SRTS), BlueRiver Acquisition (BLUA), BrainsWay (BWAY), and Allurion Technologies (ALUR). These companies are all part of the "surgical & medical instruments" industry.
Beyond Air (NASDAQ:XAIR) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment.
In the previous week, DarioHealth had 2 more articles in the media than Beyond Air. MarketBeat recorded 3 mentions for DarioHealth and 1 mentions for Beyond Air. Beyond Air's average media sentiment score of 0.62 beat DarioHealth's score of 0.22 indicating that Beyond Air is being referred to more favorably in the media.
31.5% of Beyond Air shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 19.0% of Beyond Air shares are held by company insiders. Comparatively, 15.7% of DarioHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Beyond Air has higher earnings, but lower revenue than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Beyond Air has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.
DarioHealth received 194 more outperform votes than Beyond Air when rated by MarketBeat users. However, 68.75% of users gave Beyond Air an outperform vote while only 67.04% of users gave DarioHealth an outperform vote.
Beyond Air presently has a consensus target price of $10.75, suggesting a potential upside of 739.84%. DarioHealth has a consensus target price of $4.05, suggesting a potential upside of 183.22%. Given Beyond Air's higher possible upside, research analysts clearly believe Beyond Air is more favorable than DarioHealth.
Beyond Air has a net margin of 0.00% compared to DarioHealth's net margin of -282.38%. DarioHealth's return on equity of -76.11% beat Beyond Air's return on equity.
Summary
Beyond Air and DarioHealth tied by winning 8 of the 16 factors compared between the two stocks.
Get Beyond Air News Delivered to You Automatically
Sign up to receive the latest news and ratings for XAIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XAIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beyond Air Competitors List
Related Companies and Tools
